Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test in Locally Advanced or Metastatic Non-small Cell Lung Cancer patients with EGFR Mutations. The main question it aims to answer is:
Evaluation of the Efficacy and Safety of Aumolertinib in Combination with Lastet for the Treatment of EGFR-Mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer in First-line Therapy.
Participants will be treated with a combination of Aumolertinib and Lastet.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Collaborators:
Shanghai Zhongshan Hospital The First Affiliated Hospital of Xiamen University